Verona Pharma plc
VRNA
Kedudukan dalam Saham
#2235
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Harga Saham
$106.91
Disegerakkan terakhir: 2025-10-07
Modal Pasaran
$9.09B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
GB
Perdagangan Verona Pharma plc (VRNA)
Kategori
Healthcare
Nisbah P/B bagi Verona Pharma plc (VRNA)
Nisbah P/B pada October 2026 TTM: 41.96
Menurut laporan kewangan dan harga saham terkini Verona Pharma plc, nisbah P/B semasa (TTM) ialah 41.96. Pada akhir 2023, nisbah P/B syarikat ialah 6.02.
Sejarah nisbah P/B untuk Verona Pharma plc dari 2005 hingga 2026
Nisbah P/B pada akhir setiap tahun
| Tahun | Nisbah P/B | Ubah |
|---|---|---|
| 2026 (TTM) | 41.96 | 130.17% |
| 2024 | 18.23 | 202.67% |
| 2023 | 6.02 | -19.60% |
| 2022 | 7.49 | 178.89% |
| 2021 | 2.69 | 115.77% |
| 2020 | 1.24 | -3.18% |
| 2019 | 1.29 | 3.29% |
| 2018 | 1.24 | 34.11% |
| 2017 | 0.93 | -13.81% |
| 2016 | 1.08 | -61.46% |
| 2015 | 2.79 | 192.12% |
| 2014 | 0.96 | -53.11% |
| 2013 | 2.04 | 34.88% |
| 2012 | 1.51 | 42.73% |
| 2011 | 1.06 | -15.01% |
| 2010 | 1.25 | 40.84% |
| 2009 | 0.89 | -26.97% |
| 2008 | 1.21 | 33.07% |
| 2007 | 0.91 | 31.45% |
| 2006 | 0.69 | -80.59% |
| 2005 | 3.57 | 0.00% |
Nisbah P/B untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/B | Perbezaan Nisbah P/B | Negara |
|---|---|---|---|
| 6.251 | -85.10% |
US
|
|
| 13.2547 | -68.41% |
US
|
|
| 4.208 | -89.97% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -85.27% |
NL
|
